Individuals with filaggrin-related eczema and asthma have increased long-term medication and hospital admission costs.

The presence of FLG mutations in this cohort is associated with increased prescribing for eczema and asthma. Randomized controlled trials are required to determine if these individuals could benefit from management strategies to reduce morbidity and treatment costs.